Xilio Therapeutics will implement a 1-for-14 reverse stock split at 5:00 p.m. ET on March 13, automatically combining every 14 issued and outstanding shares into one post-split share. This will reduce total common shares outstanding from approximately 73.5 million to approximately 5.2 million and trading on a split-adjusted basis will begin March 16 under the existing ticker with new CUSIP 98422T209.

The primary objective of the reverse split is to increase the per-share market price of Xilio’s common stock, enabling the company to satisfy Nasdaq Capital Market’s minimum bid price requirement and maintain continued listing.

All outstanding warrants, options and equity awards will be adjusted on a pro rata basis to reflect the 1-for-14 ratio under their respective terms. Fractional shares resulting from the split will not be issued; holders entitled to fractions will receive cash payments, and electronic and broker-held positions will be automatically updated.